In this edition:
Ciltacabtagene autoleucel in lenalidomide-refractory MM
Teclistamab + talquetamab in RRMM
GPRC5D-targeted CAR T-cell therapy for RRMM
Talquetamab + daratumumab for RRMM
Talquetamab for RRMM
Teclistamab + nirogacestat for RRMM
Linvoseltamab for RRMM
Elranatamab weekly or biweekly for RRMM
Idecabtagene vicleucel in patients with triple-class-exposed RRMM
Plasma cell leukaemia-like transcriptome and CTCs in newly diagnosed MM
Please login below to download this issue (PDF)